3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 3
10
Phase 1
8
Phase 1/2
6
Phase NA
4
Phase 4
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
22
Other hematologic neoplasm
18
Plasma cell
11
Thoracic
3
Gastrointestinal
3
Breast
3
Tumor-Agnostic
2
Genitourinary
2
Myeloid
1
Head & Neck
1
Gynecologic
1
Conditions
Prostatic Neoplasms
2
Interventions
Zoledronic Acid
15
enzalutamide
10
Leuprolide
9
Goserelin
8
bicalutamide
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Triptorelin Pamoate
6
Prednisone
6
Nivolumab
6
Abiraterone Acetate
6
luprolide acetate gel depot
5
Sunitinib
5
Magnetic Resonance Spectroscopy
5
Everolimus
5
Dutasteride
5
Specimen Handling
4
Sodium Chloride
4
Propofol
4
Prednisolone
4
Androgen Antagonists
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
pazopanib
3
fluciclovine F-18
3
darolutamide
3
cabazitaxel
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Rocuronium
3
Mitomycin
3
Midazolam
3
Flutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Dexamethasone
×
Genitourinary
×
Clear all
NCT03432949
2024-01-24
TRANCE
University Health Network, Toronto
Phase 4
Unknown
24 enrolled
NCT02441894
2017-01-24
PEGAZUS
Sanofi
Phase 4
Completed
21 enrolled